Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Potential Cardioprotective Effect of Addition of Atorvastatin in Breast Cancer Patients Treated With Doxorubicin-based Chemotherapy

NCT07668076 is registered in ClinicalTrials.gov with Damanhour University as lead sponsor.

NCT NCT07668076
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07668076 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Potential Cardioprotective Effect of Addition of Atorvastatin in Breast Cancer Patients Treated With Doxorubicin-based Chemotherapy
Lead sponsor
Damanhour University
Phase
Phase 2
Overall status
Completed
Start date
November 15, 2022
Completion date
October 20, 2024
Enrollment
44 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, doxorubicin induced cardiomyopathy